XML 39 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:      
Research and development $ 10,902 $ 8,216 $ 3,729
General and administrative 5,666 2,647 1,898
Total operating expenses 16,568 10,863 5,627
Operating loss 16,568 10,863 5,627
Finance income 216 65 76
Finance expenses (223) (1,222) (719)
Net loss before tax (16,575) (12,020) (6,270)
Income taxes (1,557) (825) (735)
Net loss for the year (15,018) (11,195) (5,535)
Net loss attributable to shareholders of Evaxion Biotech A/S (15,018) (11,195) (5,535)
Other comprehensive income that may be reclassified to profit or loss in subsequent periods (net of tax):      
Exchange differences on translation of foreign operations (18)    
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods (net of tax):      
Exchange differences on currency translation to presentation currency 413 2 (15)
Other comprehensive loss for the year, net of tax 395 2 (15)
Total comprehensive loss (14,623) (11,193) (5,550)
Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S $ (14,623) $ (11,193) $ (5,550)
Loss per share – basic and diluted $ (0.97) $ (0.81) $ (0.43)